RS66215B1 - 1-[1-(4-benziloksi-3,5-difluoro-benzoil)-4-fluoro-pirolidin-2-karbonil]-pirolidin-2-karbonitril - Google Patents
1-[1-(4-benziloksi-3,5-difluoro-benzoil)-4-fluoro-pirolidin-2-karbonil]-pirolidin-2-karbonitrilInfo
- Publication number
- RS66215B1 RS66215B1 RS20241253A RSP20241253A RS66215B1 RS 66215 B1 RS66215 B1 RS 66215B1 RS 20241253 A RS20241253 A RS 20241253A RS P20241253 A RSP20241253 A RS P20241253A RS 66215 B1 RS66215 B1 RS 66215B1
- Authority
- RS
- Serbia
- Prior art keywords
- formula
- compound
- pyrrolidine
- carbonitrile
- benzyloxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382606 | 2020-07-07 | ||
| EP21739678.7A EP4178945B1 (en) | 2020-07-07 | 2021-07-06 | 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile |
| PCT/EP2021/068577 WO2022008477A1 (en) | 2020-07-07 | 2021-07-06 | 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS66215B1 true RS66215B1 (sr) | 2024-12-31 |
Family
ID=71607883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20241253A RS66215B1 (sr) | 2020-07-07 | 2021-07-06 | 1-[1-(4-benziloksi-3,5-difluoro-benzoil)-4-fluoro-pirolidin-2-karbonil]-pirolidin-2-karbonitril |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US12459891B2 (enExample) |
| EP (1) | EP4178945B1 (enExample) |
| JP (1) | JP7628716B2 (enExample) |
| KR (1) | KR20230035604A (enExample) |
| CN (1) | CN117545738A (enExample) |
| AU (1) | AU2021303440A1 (enExample) |
| BR (1) | BR112023000335A2 (enExample) |
| CA (1) | CA3185064A1 (enExample) |
| ES (1) | ES2997164T3 (enExample) |
| HR (1) | HRP20241527T1 (enExample) |
| HU (1) | HUE068953T2 (enExample) |
| IL (1) | IL299035B1 (enExample) |
| MA (1) | MA60250B1 (enExample) |
| MX (1) | MX2023000261A (enExample) |
| RS (1) | RS66215B1 (enExample) |
| SM (1) | SMT202400460T1 (enExample) |
| TW (1) | TWI893162B (enExample) |
| WO (1) | WO2022008477A1 (enExample) |
| ZA (1) | ZA202213708B (enExample) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6159938A (en) | 1994-11-21 | 2000-12-12 | Cortech, Inc. | Serine protease inhibitors comprising α-keto heterocycles |
| DE19603510A1 (de) | 1996-02-01 | 1997-08-07 | Knoell Hans Forschung Ev | Die Verwendung von Terrecyclolsäure A und Terrecyclolsäure A-Derivate als neue Inhibitoren der humanen Prolyl-Oligopeptidase |
| FI20011466A0 (fi) | 2001-07-04 | 2001-07-04 | Orion Corp | Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä, niiden valmistusmenetelmiä ja käyttö |
| FI20030014A0 (fi) | 2003-01-03 | 2003-01-03 | Orion Corp | Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä |
| FI20031018A0 (fi) | 2003-07-04 | 2003-07-04 | Orion Corp | Parannus aivovammasta toipumiseen |
| WO2005027934A1 (ja) | 2003-09-24 | 2005-03-31 | Nippon Kayaku Kabushiki Kaisha | プロリルオリゴペプチダーゼ阻害剤 |
| US7667044B2 (en) | 2003-11-03 | 2010-02-23 | Probiodrug Ag | Compounds for the treatment of neurological disorders |
| ES2302473B1 (es) | 2006-12-22 | 2009-06-12 | Universidad De Barcelona | Agente terapeutico para el tratamiento del desorden afectivo bipolar en mamiferos. |
| EP2730571A1 (en) * | 2012-11-12 | 2014-05-14 | Universitat De Barcelona | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives |
-
2021
- 2021-07-06 AU AU2021303440A patent/AU2021303440A1/en active Pending
- 2021-07-06 RS RS20241253A patent/RS66215B1/sr unknown
- 2021-07-06 WO PCT/EP2021/068577 patent/WO2022008477A1/en not_active Ceased
- 2021-07-06 HR HRP20241527TT patent/HRP20241527T1/hr unknown
- 2021-07-06 MX MX2023000261A patent/MX2023000261A/es unknown
- 2021-07-06 TW TW110124773A patent/TWI893162B/zh active
- 2021-07-06 EP EP21739678.7A patent/EP4178945B1/en active Active
- 2021-07-06 HU HUE21739678A patent/HUE068953T2/hu unknown
- 2021-07-06 JP JP2022581707A patent/JP7628716B2/ja active Active
- 2021-07-06 CA CA3185064A patent/CA3185064A1/en active Pending
- 2021-07-06 SM SM20240460T patent/SMT202400460T1/it unknown
- 2021-07-06 CN CN202180047448.7A patent/CN117545738A/zh active Pending
- 2021-07-06 US US18/004,658 patent/US12459891B2/en active Active
- 2021-07-06 MA MA60250A patent/MA60250B1/fr unknown
- 2021-07-06 ES ES21739678T patent/ES2997164T3/es active Active
- 2021-07-06 BR BR112023000335A patent/BR112023000335A2/pt unknown
- 2021-07-06 KR KR1020237003988A patent/KR20230035604A/ko active Pending
-
2022
- 2022-12-12 IL IL299035A patent/IL299035B1/en unknown
- 2022-12-19 ZA ZA2022/13708A patent/ZA202213708B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202213708B (en) | 2024-04-24 |
| IL299035A (en) | 2023-02-01 |
| TWI893162B (zh) | 2025-08-11 |
| JP7628716B2 (ja) | 2025-02-12 |
| SMT202400460T1 (it) | 2025-01-14 |
| EP4178945B1 (en) | 2024-08-28 |
| BR112023000335A2 (pt) | 2023-01-31 |
| US12459891B2 (en) | 2025-11-04 |
| AU2021303440A1 (en) | 2023-02-02 |
| CN117545738A (zh) | 2024-02-09 |
| EP4178945C0 (en) | 2024-08-28 |
| US20230250058A1 (en) | 2023-08-10 |
| WO2022008477A1 (en) | 2022-01-13 |
| ES2997164T3 (en) | 2025-02-14 |
| EP4178945A1 (en) | 2023-05-17 |
| CA3185064A1 (en) | 2022-01-13 |
| HUE068953T2 (hu) | 2025-02-28 |
| MX2023000261A (es) | 2023-04-13 |
| JP2023533932A (ja) | 2023-08-07 |
| MA60250B1 (fr) | 2024-11-29 |
| TW202216689A (zh) | 2022-05-01 |
| KR20230035604A (ko) | 2023-03-14 |
| HRP20241527T1 (hr) | 2025-01-03 |
| IL299035B1 (en) | 2026-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7472103B2 (ja) | トロポミオシン受容体キナーゼ(trk)分解化合物とその使用方法 | |
| US10611727B2 (en) | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives | |
| JP7638265B2 (ja) | 神経変性疾患の治療におけるペプチド模倣化合物(r)-2-アミノ-n-((s)-l-(((s)-5-アミノ-l-(3-ベンジル-1,2,4-オキサジアゾール-5-イル)ペンチル)アミノ)-3-(4-ヒドロキシ-2,6-ジメチルフェニル)-i-オキソプロパン-2-イル)-5-グアニジノペンタンアミド | |
| US20070293486A1 (en) | Alpha-Keto Carbonyl Calpain Inhibitors | |
| EP4178945B1 (en) | 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile | |
| RU2841064C1 (ru) | 1-[1-(4-бензилокси-3,5-дифтор-бензоил)-4-фтор-пирролидин-2-карбонил]-пирролидин-2-карбонитрил | |
| US20230212225A1 (en) | Peptide compostions and methods for treating tauopathies | |
| HK40084881B (en) | 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile | |
| HK40084881A (en) | 1-[1-(4-benzyloxy-3,5-difluoro-benzoyl)-4-fluoro-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile | |
| US20230073000A1 (en) | Improved Cell-Permeable Modified Parkin Recombinant Protein for Treatment of Neurodegenerative Diseases and Use Thereof | |
| HK1214597B (en) | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives | |
| CN119451944A (zh) | Prep结合配体 |